1,226 search results for “drugs” in the Public website
-
More effective blocking of CCR2 receptor
The discovery of new medicines is a tedious and lengthy process. On average, over 10,000 molecules need to be studied for one to become a drug and reach the patient. Part of that process are the very costly clinical trials in humans, and candidate drugs often fail due to side effects or lack of efficacy.…
-
Novel Chemical Modalities
The Novel chemical modalities research group is headed by Assistant Professor Sebastian Pomplun. Sebastian started at the division of Medicinal Chemistry within the LACDR in September 2021. His lab develops technologies for the discovery of novel chemical modalities that can address challenging drug…
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Sebastian Pomplun
Science
s.j.pomplun@lacdr.leidenuniv.nl | +31 71 527 4651
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
PhD defence
-
Characterization and skin permeation of ketoprofen-loaded vesicular systems
PURPOSE: To determine the effect of elasticity on the skin permeation of ketoprofen from surfactant-based vesicular formulations and elastic liposomes.
-
Research
The current projects of the Molecular Physiology group focus on proteins of the endocannabinoid system, kinases and antibacterial targets. MSc- and BSc-students can contact Jessica van Krimpen-Kraaijenoord to apply for research internships.
-
A much-needed new class of antibiotics
Antimicrobial resistance (AMR) is the phenomenon that pathogens become insensitive to the antibiotics that we use against them. A growing number of pathogens is becoming resistant, with methicillin-resistant S. aureus (MRSA) as the most famous example. But while the threat of AMR represents a slow-moving…
-
Single cell technologies for mechanobiology and mechanopharmacology
Mechanobiology is a major area in biology, however, mechanics is currently a missing element in drug development pipelines. This has led to a high cost for the society. Mechanotoxicity of drugs often appears as a long-term side effect of drugs, and has led to removal of drugs from the market. Furthermore,…
-
Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery
Promotor: C.A.J. Knibbe, Co-promotores: H.P.A. van Dongen, B. van Ramshorst
-
Prediction of brain target site concentrations on the basis of CSF PK: impact of mechanisms of blood-to-brain transport and within brain distribution
Promotor: Prof.dr. M. Danhof, Co-promotor: E.C.M. de Lange
-
Systems pharmacology of human neuroendocrine disease entities
An important hormone excreting gland in the human body is the pituitary
-
BioTherapeutics (MSc)
The master’s specialisation BioTherapeutics at Leiden University is a two-year programme which trains students in research in specific drug delivery techniques. The programme also examines the development of new therapeutic approaches to treat immune-based disorders, such as atherosclerosis, metabolic…
-
Oncode Accelerator
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Contact
Division contact information & address
-
New techniques for tuberculosis treatment
About nine million people worldwide contract tuberculosis each year. Research into new treatment for this disease has received fresh stimulus with more efficient techniques and a new understanding of how the tuberculosis bacteria works.
-
Systems Biomedicine and Pharmacology (MSc)
The two-years master’s specialisation System Biomedicine and Pharmacology at Leiden university focuses on predicting drug response with computational modelling, developing individualised therapies, and developing innovative analytical tools for personalised health strategies.
-
Role of leukocytes in metastasis formation in a zebrafish
How do macrophages and neutrophils contribute to metastatic onset?
-
Allosteric modulation and ligand binding kinetics at the Kv11.1 channel
Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Dosing considerations for preterm neonates: from pharmacometrics to clinical practice
Prematurely born neonates require, amongst others, pharmaceutical therapy. Dosing guidelines for these therapies are often based on data from term born neonates or older infants, while these are not necessarily similar to prematurely born neonates.
-
Strategy
The division of BioTherapeutics consists of the former divisions Biopharmaceutics and Drug Delivery Technology.
-
Seeking new concepts to treat diseases
Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’
- Research
-
Coiled-coil biomaterials for biological applications
This dissertation contains four works during my PhD. Different biomaterials have been designed based on coiled-coil peptides. These biomaterials have a range of applications, inclusing drug delivery, cell sorting to cell-cell fusion.
-
Quantitative Clinical Pharmacology
The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…
-
Research
Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…
-
Education
Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.
-
History
Life Sciences Artificial Intelligence Data Science
-
Development of hyaluronan-based dissolving microneedle arrays for dermal vaccination
Dissolving microneedles are a subgroup of microneedle types that completely dissolve within the skin. During this dissolving process the vaccine, stored in the needle matrix, is released into the skin.
-
Phenomix Field Lab offers promising healthcare solutions
In the Phenomix Medical Delta Field Lab, which was officially opened on Thursday 9 July, scientists, healthcare institutions and businesses work together to develop innovative applications in the field of metabolomics. This research field makes it possible to determine which drugs will be effective…
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
Bio-Pharmaceutical Sciences (BSc)
As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!
- GTGC lunch seminar: Santino Regilme on Global Drug Wars
-
Cannabinoid receptor 2 as a ‘drugable’ target: kinetic profile of novel receptor ligands
Supervisor: Andrea Martella
-
Novel analytical approaches to characterize particles in biopharmaceuticals
Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
Chemokine signaling in Tuberculosis and Salmonella infection
Who benefits from CXCR/CXCL chemokine signaling during infection: host or pathogen?
-
How to develop cancer drugs with less side effects
Lecture, Tuesday Talks: Science Insights
-
Cancer cells: A closer look
What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.
-
Prediction of human gut (colon cancer) target site concentrations and PKPD relationships
The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.
-
Key publications
Key publications of the Antiviral Pharmacology group.
-
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474, SCIENCE, 2017
The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered…
-
NACTAR: The lugdunomycins: a new class of polyketide antibiotics with unique chemical scaffold
Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.
-
Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome
Fungal infections pose a significant threat to individuals with compromised immune systems and despite advancements in diagnosis and treatment, they continue to jeopardize patient’s health.
-
Quantitative pharmacology of antimicrobials
Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.
-
Exploration of the endocannabinoid system using metabolomics
To increase clinical success rate of drugs, a better understanding of drug action mechanism and disease dynamics is required. Metabolomics, which studies small molecules involved in biochemical processes in organisms, has shown to be a useful tool for this better understanding.
-
Amphiphilic miktoarm star copolymers
Within this project, PeptoMiktoStars were realized through an orthogonal protecting group strategy and should be investigated further regarding their potential as drug delivery systems in the field of drug delivery to inflamed areas in cancer, bacterial infections or autoimmune diseases.